DRUG SURVIVAL ON FIRST TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS: COMPARISON ACROSS ETANERCEPT, ADALIMUMAB, GOLIMUMAB AND INFLIXIMAB

被引：0
|
作者：
Garcia-Porrua, C. [1 ]
Maceiras-Pan, F. [2 ]
Fernandez-Dominguez, L. [3 ]
Mosquera-Martinez, J. A. [4 ]
Correa-Rey, B. [5 ]
Pombo-Suarez, M. [6 ]
Pinto-Tasende, J. [7 ]
机构：
[1] HU Locus Augusti, Rheumatol, Lugo, Spain
[2] CHU Vigo, Rheumatol, Vigo, Spain
[3] CHU Ourense, Rheumatol, Ourernse, Spain
[4] CHU Pontevedra, Rheumatol, Pontevedra, Spain
[5] CHU Arquitecto Marcide Naval, Rheumatol, Ferrol, Spain
[6] CHU Santiago, Rheumatol, Santiago De Compostela, Spain
[7] INIBIC XXI A Coruna, Rheumatol, La Coruna, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.4951
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0333
引用
收藏
页码：1031 / 1031
页数：1
相关论文
共 50 条
  • [31] Infliximab, Etanercept, and Adalimumab switching in patients with rheumatoid arthritis in the CORRONA database
    Dabbous, O.
    Kremer, J.
    Rambharose, J.
    El Taha, M.
    Reed, G.
    Tang, B.
    Thomson, H.
    Domdey, A.
    Rahman, M.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 42 - 42
  • [32] Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab
    Katsicas, Maria M.
    Russo, Ricardo A. G.
    CLINICAL RHEUMATOLOGY, 2009, 28 (08) : 985 - 988
  • [33] COMPARATIVE DRUG SURVIVAL OF TNF INHIBITORS AND SECUKINUMAB IN BIOLOGIC NAIVE PATIENTS WITH ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS
    Cheila, M.
    Douglas, K.
    Koutsianas, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 723 - 724
  • [34] Predictors for terminating therapy of etanercept and infliximab in psoriatic arthritis patients.
    Kristensen, Lars Erik
    Geborek, Pierre
    Nilsson, Jan- ke
    Saxne, Tore
    Compagno, Michele
    Jacobsson, Lennart
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S721 - S722
  • [35] Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis
    Curry, Philippa D. K.
    Hum, Ryan M.
    Morris, Andrew P.
    Jani, Meghna
    Chinoy, Hector
    Barton, Anne
    Bluett, James
    RHEUMATOLOGY, 2023,
  • [36] The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis
    Vergel, Y. Bravo
    Hawkins, N. S.
    Claxton, K.
    Asseburg, C.
    Palmer, S.
    Woolacott, N.
    Bruce, I. N.
    Sculpher, M. J.
    RHEUMATOLOGY, 2007, 46 (11) : 1729 - 1735
  • [37] Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: Preliminary data
    Delaunay, C
    Farrenq, V
    Marini-Portugal, A
    Cohen, JD
    Chevalier, X
    Claudepierre, P
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (11) : 2183 - 2185
  • [38] The Efficacy Of Etanercept In Patients With Juvenile Idiopathic Arthritis With Inadequate Response To Infliximab As a First TNF Inhibitor
    Alekseeva, Ekaterina
    Bzarova, Tatyana
    Fetisova, Anna
    Sleptsova, Tatyana
    Valieva, Saniya
    Isayeva, Kseniya
    Denisova, Rina
    Mitenko, Elena
    Chistyakova, Evgeniya
    Taybulatov, Nikolay
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S123 - S124
  • [39] Retention on Adalimumab, Etanercept, Golimumab and Infliximab in Two Eras - Experience of Patients with Rheumatoid Arthritis from a Real-World Database RHUMADATA®
    Choquette, Denis
    Bessette, Louis
    Coupal, Louis
    Garces, Kirsten
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [40] Tocilizumab Use in Patients with Rheumatoid Arthritis Having Failed One Previous Anti-TNF Agent: Comparison with Adalimumab, Etanercept and Infliximab.
    Choquette, Denis
    Payette, Marie-Pier
    Raynauld, Jean-Pierre
    Pelletier, Jean-Pierre
    Bessette, Louis
    Villeneuve, Edith
    Haraoui, Boulos
    Fortin, Isabelle
    Remillard, Marie-Anais
    Sauvageau, Diane
    Coupal, Louis
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S217 - S217
12345